$RDGL News

SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test

Vivos to buy 50% stake in SOD Sciences’ pseudohypoxia test

Vivos Therapeutics Announces Material Debt Reduction

Vivos Inc. Peer-Reviewed PrecisionGel Publication Strengthens Scientific Case for Drug Delivery Platform

Vivos Inc. Announces Peer-Reviewed Publication Characterizing PrecisionGel™ Polymer Platform in Elsevier Journal of Drug Delivery Science and Technology

Vivos Begins IsoPet Shipments and Secures India Manufacturing Authorization

Vivos Inc. Achieves Two Major Operational Milestones: First IsoPet® Shipments from New U.S. Production Facility and Authorization from India’s Nuclear Regulatory Authority for International Manufacturing Center

Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update - Correction

Vivos Reports FDA IDE Approval and Expands Precision Radionuclide Therapy Programs

Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update

Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™

Vivos Receives Washington Radioactive Materials License for IsoPet Manufacturing, Enabling Domestic Production Expansion (RDGL)

Vivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet® Manufacturing

Vivos Gets State Of Washington Radioactive Materials License To Manufacture IsoPet

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™

Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites

Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™

Vivos Inc Updates Human Therapy Progress in India

Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals